Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited, a Melbourne-based biopharmaceutical company, has updated its Securities Dealing Policy in line with ASX Listing Rule 12.10. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, with its lead imaging product Illuccix® already approved in the U.S., Australia, and Canada. Investors are encouraged to visit Telix’s website for further information and stay updated on the latest developments.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
